Incyte to Present Oncology Data at ESMO Congress 2026
Incyte will present new oncology findings at the European Society of Medical Oncology Congress in Madrid, scheduled for October 23–27. The company plans four rapid oral presentations on investigational therapies INCB161734, a KRAS G12D inhibitor, and INCA33890, a TGFbetaR2 and PD-1 bispecific antibody, in ongoing Phase 3 trials. Incyte also scheduled an investor webcast for October 26 to discuss the data and portfolio updates.
Why it matters
The presentations could provide updates on Incyte’s late-stage oncology pipeline, and the company says the data will inform ongoing Phase 3 studies. The materials do not report efficacy or safety results, so the direct clinical impact remains unknown.
Key facts
- 1The ESMO Congress is scheduled for October 23–27 in Madrid. gurufocus.com
- 2Incyte plans four rapid oral presentations focused on INCB161734 and INCA33890. gurufocus.com
- 3An investor webcast is scheduled for October 26. tradingview.com
- 4The presentations include INCB161734 studies in colorectal and pancreatic cancers, INCA33890 work in MSS CRC, and INCB123667 research in ovarian cancer. marketscreener.com
Open questions
- The materials do not provide the efficacy, safety, or other clinical results that Incyte will present.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.